Biotech Acquisition Co

Biotech Acquisition Co. is a blank check company, which engages in the effectuation of a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one business. The company was founded on September 3, 2020 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK , Jan. 4, 2023 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in connection with a proposed extension (the "Extension") of the time period the Company has to complete an initial business combination, as described in the Proxy Statement (as defined below), IREEM LLC, which has entered into an agreement to acquire the current sponsor's interest in the Company (as described in the Proxy Statement), will deposit into the Company's trust account (the "Trust Account") for each additional month the lesser of (i) an aggregate of $457,500 or (ii) $0.055 per share that remains outstanding and is not redeemed in connection with the Extension. The amount deposited per share will depend on the number of public shares that remain outstanding after redemptions in connection with the Extension and the length of the extension period that will be needed to complete an initial business combination.

Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment

NEW YORK and SOUTH SAN FRANCISCO, Calif. , June 13, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, Calif.

Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement

Extraordinary General Meeting of BAC's shareholders postponed until a to-be-determined later date NEW YORK and SOUTH SAN FRANCISCO, Calif. , June 2, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, Calif.

Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination

NEW YORK , May 24, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (" BAC "), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a submission to the United States Securities and Exchange Commission (" SEC ") of a prospectus supplement containing information supplements and updates to the information contained in the proxy statement/prospectus dated May 9, 2022, included in Amendment No. 4 to the registration statement on Form S-4 (File No.

Biotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ATS2022--Blade Therapeutics announces new data from preclinical studies that highlight differentiating characteristics of cudetaxestat in poster at ATS 2022.

Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ATS2022--Blade Therapeutics presented data from phase 1 & preclinical DDI studies of cudetaxestat at American Thoracic Society 2022 International Conference

Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

Extraordinary General Meeting of BAC's shareholders is scheduled for June 1, 2022, at 10:00 a.m., Eastern Time Post-closing company will be renamed "Blade Biotherapeutics, Inc." upon Business Combination closing, with common stock and warrants expected to trade on the Nasdaq Global Market under ticker symbols "BBTX" and "BBTXW" Post-closing company has secured up to $75 million in financing under a committed equity facility with an affiliate of Cantor Fitzgerald NEW YORK and SOUTH SAN FRANCISCO, Calif.

Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity F

NEW YORK , April 4, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (" BAC "), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securities and Exchange Commission, the first amendment to its registration statement on Form S-4, filed on March 15, 2022 (as amended, the "registration statement"), relating to its previously announced proposed business combination with Blade Therapeutics, Inc. (" Blade "), a biopharmaceutical company based in South San Francisco, CA. BAC and Blade announced their definitive merger agreement on November 8, 2021.

Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #clinicalstudy--Blade Therapeutics, Inc. (“Blade” or “Company”), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced receipt of feedback from the FDA regarding the company's end-of-phase 1 data package for cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for treatment of IPF and other fibrotic diseases. The FDA response letter

Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ATS2022--Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that the company will present data for cudetaxestat in three posters at the American Thoracic Society (ATS) 2022 International Conference, May 13-18, 2022, The Moscone Center, in San Francisco. The poster presentations will include new data from a phase 1 drug-drug interaction c

Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

NEW YORK , March 16, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (" BAC "), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securities and Exchange Commission, a registration statement on Form S-4 relating to its previously announced proposed business combination with Blade Therapeutics, Inc. (" Blade "), a biopharmaceutical company based in South San Francisco, CA. BAC and Blade announced their definitive merger agreement on November 8, 2021.

Biotech Acquisition Company Announces Public Filing of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #OPCOHC2022--Blade to present at Oppenheimer's 32nd Annual Healthcare Conference on March 15 and at Barclays Global Healthcare Conference on March 16, 2022.

Blade Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #clinicalstudy--Blade Therapeutics, Inc. today announced the successful completion of a phase 1 drug-drug interaction clinical study of cudetaxestat.

Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis

NEW YORK, Jan. 3, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (" BAC "), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a confidential submission to the United States Securities and Exchange Commission (" SEC "), for receipt by the SEC on December 27, 2021, of a draft registration statement on Form S-4 (the " Registration Statement ") relating to its previously announced proposed business combination with Blade Therapeutics, Inc. (" Blade "), a biopharmaceutical company based in South San Francisco, CA.  About Biotech Acquisition Company Biotech Acquisition Company raised $230 million in its initial public offering in January 2021.

Biotech Acquisition Company Announces Confidential Submission of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #clinicalstudy--Blade announces positive topline data from a phase 1 drug-drug interaction clinical study of cudetaxestat.

Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis

New York, New York--(Newsfile Corp. - November 9, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Biotech Acquisition Company (NASDAQ: BIOT) ("Biotech Acquisition" or the "Company") stock prior to November 8, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Biotech Acquisition with Blade Therapeutics,

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Biotech Acquisition Company with Blade Therapeutics, Inc.

News for Biotech Acquisition Co Stock (BIOT)